2015 EASD In Review: CV Risk management in t2dm

Program Overview

EASD Annual Meeting

T2DM and CVD

Research at EASD Related to T2DM and CV Risk

Research at EASD Related to T2DM and CV Risk

Amelioration of Hyperglycemia With SGLT2 Inhibition Prevents Atherosclerosis in Diabetic Mice Independent of Insulin Action

Increased Risk of CV-related Events With SUs Compared To Other Antihyperglycemic Drugs

Increased Risk of CV-related Events With SUs Compared With Other Antihyperglycemic Drugs (cont)

Second-line Treatment With SUs vs DPP-4 Inhibitors Is Associated With Risk of CVD, All-cause Mortality and Severe Hypoglycemia

Adjusted Risk of Fatal/Nonfatal CVD in Patients on Second-Line Treatment With MET + SU vs MET + DPP-4

Treatment Characteristics and Outcomes With SU vs MET in Incident T2DM: Results of the German CREST Study

German CREST Study: Study Population Treatment Characteristics

German CREST Study: Patient Outcomes

No Difference In MACE With BIL vs Comparator Insulins In T1DM or T2DM

Summary of HRs for MACE-plus Events by Study

EMPA-REG OUTCOME Study: Empagliflozin, CV Outcomes, and Mortality in T2DM

EMPA-REG OUTCOME: Trial Design

EMPA-REG OUTCOME: Primary Endpoint, 3-Point MACE*

EMPA-REG OUTCOME: CV Death

EMPA-REG OUTCOME: CV Death By Treatment Group

EMPA-REG OUTCOME: CV Death, MI, and Stroke

EMPA-REG OUTCOME: All-cause Mortality

EMPA-REG OUTCOME: Hospitalizations for HF

EMPA-REG OUTCOME Study: Summary

Ongoing CV Outcomes Trials for New Antihyperglycemic Agents

Abbreviations

Abbreviations (cont)

Abbreviations (cont)